Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.56 |
| ▸ | DYRK2 | Q92630 | 8/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 7/20 | 0.56 |
| ▸ | DYRK3 | O43781 | 6/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.56 |
| ▸ | CDK2 | P24941 | 6/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.56 |
| ▸ | CDK9 | P50750 | 4/20 | 0.56 |
| ▸ | FYN | P06241 | 10/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136464 | 0.80 | DYRK1A (0.51) | DYRK1ADYRK2CDK5CDK5R1DYRK1B | |
| SCHEMBL16371211 | 0.80 | DYRK1A (0.48) | DYRK1ADYRK2CDK5CDK5R1DYRK1B | |
| SCHEMBL3513641 | 0.75 | FYN (0.74) | FYN | |
| SCHEMBL13234223 | 0.75 | FYN (0.61) | DYRK1ADYRK2CDK5CDK5R1DYRK1B | |
| SCHEMBL103153 | 0.75 | DYRK1A (0.60) | DYRK1ADYRK2CDK5CDK5R1DYRK1B | |
| SCHEMBL16388818 | 0.75 | AAK1 (0.62) | — | |
| SCHEMBL17783093 | 0.75 | AAK1 (0.62) | — | |
| SCHEMBL9902839 | 0.74 | DYRK1A (0.59) | DYRK1ADYRK2CDK5CDK5R1DYRK1B | |
| SCHEMBL24885918 | 0.73 | DYRK1A (0.54) | DYRK1ADYRK2CDK5CDK5R1DYRK1B | |
| SCHEMBL102386 | 0.73 | DYRK1A (0.51) | DYRK1ADYRK2CDK5CDK5R1DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253027-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| EP-3019475-A1 | ARYL AMIDE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006100-A1 | ARYL AMIDE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | AAK1, ADCK1, ANKK1 | DYRK1A 449/4885DYRK2 412/4885CDK5 829/4885 |
| US-10253027-B2 | Aryl lactam kinase inhibitors | AAK1, ADCK1, ANKK1 | DYRK1A 449/4885DYRK2 412/4885CDK5 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.